<DOC>
	<DOC>NCT02627287</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to compare Injections with the Medical Device DV3316 Pen-injector versus FlexPen®.</brief_summary>
	<brief_title>A Comparative Trial Focusing on Injections With the Medical Device DV3316 Pen-injector Versus FlexPen®</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<criteria>Male or female aged 1874 years (both included) at the time of signing informed consent T1DM (Type 1 Diabetes Mellitus) or T2DM (Type 2 Diabetes Mellitus) (as diagnosed clinically) at least 12 months prior to screening Daily selfinjection(s) with antidiabetic drug (insulin or GlucagonLike Peptide1 (GLP 1) analogues) in peninjector or vial/syringe for at least 12 months Caucasians Body Mass Index (BMI) at least 18.5 kg/m^2 Known or suspected hypersensitivity to test placebo solution incl. mcresol and phenol or related products (placebo) Female who is pregnant,, breastfeeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice) Known urticaria factitive or abnormal reactions to mechanical trauma Haemophilia and any diseases affecting blood coagulation Anticoagulant or inhibitors of platelet aggregation treatment on the day of the visit Intake of any painrelieving or analgesic drugs on the day of the site visit Skin diseases and infections of the skin in the injection site areas (abdomen and thighs) Lipodystrophia in the injection site areas (abdomen and thighs)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>